-
Featured
Low-risk Incidental Prostate Cancer in Men with Bladder Cancer May Be Associated with Longer Survival
Men with bladder cancer who have low-risk prostate cancer detected incidentally by radical cystoprostatectomy may actually have a more favorable prognosis than those who do not.
-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
New Target Discovered for Prostate Cancer Immunotherapy
Genitourinary pathologists at Massachusetts General Hospital are the first to demonstrate that PD-L1 expression is highly prevalent in prostate tumor-associated nerves. Such nerves may represent an important target for immunotherapy regimens.
-
Study Explores Value of Prostate Cancer Screening With MRI
The Prostate Cancer Genetics Program at Massachusetts General Hospital explores whether MRI prostate cancer screening detects disease earlier than standard tests in men with genetic mutations linked to prostate cancer.
-
Auto-Contouring Model Performs Well for Prostate Cancer Patients Who Receive Radiopaque Hydrogel Spacer
Yi Wang, PhD, Jason A. Efstathiou, MD, DPhil, and colleagues have validated a CT-based deep learning model that provides automated contouring when planning radiation therapy for prostate cancer patients who receive the SpaceOAR Vue rectal spacer.
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
Mass General Cancer Center Contributors
-
Adam Scott Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Director of Research and Urologic Oncologist, Department of Urology, Massachusetts General Hospital
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
